In fact, a group of renowned oncologists in the breast cancer field [International Ki67 Work Group (IKWG)] declared that the IHC-based Ki67 “has limited value for treatment decisions due to questionable analytical validity” (13). This evidence concerns the gene MKI67 and breast cancer.